Prostate cancer vaccines in combination with additional treatment modalities

被引：15
|
作者：
Uhlman, Matthew A. [1 ]
Bing, Megan T. [1 ]
Lubaroff, David M. [1 ,2 ,3 ]
机构：
[1] Univ Iowa, Dept Urol, Iowa City, IA 52242 USA
[2] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA
[3] Univ Iowa, Holden Comprehens Canc Ctr, Iowa City, IA 52242 USA
来源：
IMMUNOLOGIC RESEARCH | 2014年 / 59卷 / 1-3期
关键词：
Prostate cancer; Immunotherapy; Cancer vaccines; Combination therapy; AUTOLOGOUS CELLULAR IMMUNOTHERAPY; SIPULEUCEL-T; IMMUNOSTIMULATORY PROPERTIES; ANTITUMOR-ACTIVITY; INCREASED SURVIVAL; RADIATION-THERAPY; ACID-PHOSPHATASE; DOUBLE-BLIND; PHASE-II; DOCETAXEL;
D O I：
10.1007/s12026-014-8532-1
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Immunotherapy has been investigated in both preclinical studies and clinical trials as a new therapy for prostate cancer. Vaccines, including those that utilize dendritic cells, viruses, or DNA, immunize against prostate-specific antigen and prostatic acid phosphatase. The vaccines have long been studied as monotherapy for the cancer, but increasingly more trials have been initiated in combination with other modalities. These include radiation, chemotherapy, and androgen deprivation therapy. This review describes and discusses the various combinations of vaccine immunotherapies.
引用
收藏
页码：236 / 242
页数：7
相关论文
共 50 条
  • [31] Integrating Immunotherapies in Prostate Cancer
    Strauss, Julius
    Madan, Ravi A.
    CURRENT ONCOLOGY REPORTS, 2015, 17 (10)
  • [32] Promising immunotherapy for prostate cancer
    Henegan, John C.
    Sonpavde, Guru
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2018, 18 (02) : 109 - 120
  • [33] Current opinion and mechanistic interpretation of combination therapy for castration-resistant prostate cancer
    Xu, Jin
    Qiu, Yun
    ASIAN JOURNAL OF ANDROLOGY, 2019, 21 (03) : 270 - 278
  • [34] Prostate cancer vaccines Update on clinical development
    Geary, Sean M.
    Salem, Aliasger K.
    ONCOIMMUNOLOGY, 2013, 2 (05):
  • [35] Prostate cancer perspectives after chaarted: Optimizing treatment sequence
    Vazquez Estevez, Sergio
    Anido Herranz, Urbano
    Fernandez Calvoc, Ovidio
    Afonso Afonso, Francisco Javier
    Santome Couto, Lucia
    Lazaro Quintela, Martin
    Leon Mateos, Luis
    Macia Escalante, Sonia
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 107 : 119 - 127
  • [36] Treatment strategies for DNA repair-deficient prostate cancer
    Teply, Benjamin A.
    Antonarakis, Emmanuel S.
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (08) : 889 - 898
  • [37] Immunotherapy in prostate cancer: challenges and opportunities
    Noguchi, Masanori
    Koga, Noriko
    Moriya, Fukuko
    Itoh, Kyogo
    IMMUNOTHERAPY, 2016, 8 (01) : 69 - 77
  • [38] Tissue Vaccines for Prevention and Treatment of Prostate Cancer
    Suckow, M. A.
    Hall, P.
    Hiles, M. C.
    VACCINE, 2008,
  • [39] Immunotherapy in the treatment of advanced prostate cancer
    Djavan, Bob
    Nelson, Kathleen
    Kazzazi, Amir
    Bruhn, Aron
    Sadri, Helen
    Gomez-Pinillos, Alejandro
    Ferrari, Anna C.
    CANADIAN JOURNAL OF UROLOGY, 2011, 18 (05) : 5865 - 5874
  • [40] Treatment of metastatic prostate cancer in 2013
    Cathomas, R.
    Steuber, T.
    Gillessen, S.
    ONKOLOGE, 2013, 19 (09): : 756 - 761
12345